english.prescrire.org > Spotlight > 100 most recent > The Prescrire Awards for 2022: no "Pilule d'Or" Awards, one drug on the "Honours List". Details in the March issue of Prescrire International

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

The Prescrire Awards for 2022: no "Pilule d'Or" Awards, one drug on the "Honours List". Details in the March issue of Prescrire International

Prescrire Awards This year, none of the drugs we examined represented a major therapeutic advance justifying a Pilule d'Or ("Golden Pill" Award). One drug made the Honours List, while one other was cited as Noteworthy.

Each month, the not-for-profit French journal Prescrire publishes systematic, independent analyses of the available evidence regarding new drugs, newly authorised indications for drugs already on the market, and new forms or new dose strengths of existing drugs.

The goal is to select, amidst the multitude of new products, those which deserve to be added to the list of useful therapeutic options, or ought to be used in place of other drugs.

The annual Prescrire Awards recognise drugs, drug packaging and drug information singled out for notice by Prescrire's editorial staff. The Prescrire Awards for 2022 in Paris were announced on 1st February 2023.

 "Pilule d'Or" Awards 

The "Pilule d'Or" ("Golden Pill") is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available.

  • No drug represented a major therapeutic advance

Honours List

Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.

  • PAXLOVID° (nirmatrelvir + ritonavir) - Pfizer
     

Noteworthy

Drugs that are deemed "Noteworthy" provide a modest improvement in patient care.

  • ONUREG° (azacitidine) - Bristol-Myers Squibb

 

For details, see:
Le Palmarès Prescrire
> The Prescrire Awards for 2022

 

©Prescrire 1 March 2023

Source: "The Prescrire Awards" Prescrire International 2023; 32 (246): 80-81. Free.

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook Share on  Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >